Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer is no: increasing semaglutide before four weeks is not in line with the licensed titration schedule, and doing so does not appear to improve outcomes. The Wegovy prescribing schedule (confirmed in the UK SmPC and reflected in the NHS's patient guidance on semaglutide) spaces dose increases roughly four weeks apart for a clear clinical reason. Two weeks is simply not long enough for your system to settle at a new dose, and moving up early typically means more side effects rather than faster weight loss. Your prescriber sets the pace, not the calendar.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The titration schedule for Wegovy (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg) was not drawn up arbitrarily. The STEP 1 trial (published in the New England Journal of Medicine, involving over 1,900 adults with obesity) used that same ~four-week interval at each step, and the roughly 15% average body-weight reduction seen over 68 weeks was built on that pacing. There is no published evidence that compressing the schedule to two weeks produces faster net weight loss; the data that does exist points to worse tolerability when patients move up before their GI tract has adapted.
The starter dose of 0.25 mg is not intended to drive significant weight loss on its own, its job is to let the body adjust to the medicine. Nausea and vomiting are most pronounced early in treatment and after each increase, typically easing within a couple of weeks. Moving to the next dose before that settling period is complete stacks two waves of adjustment on top of each other, which is why the schedule exists.
This is a question our prescribers hear most weeks: patients feel well after ten days and wonder whether increasing their semaglutide dose early is a reasonable next step. The honest answer is that feeling well is the cue to stay the course, not to move faster.
In exceptional cases, a prescriber may adjust timing, for example, extending a step rather than shortening it, if side effects have been difficult. Moving up early, however, is not standard practice and is not something a patient should attempt without direct prescriber authorisation. The broader question of whether any early increase before four weeks is ever appropriate comes down to individual clinical judgement, not a general rule that permits it.
Self-adjusting any prescription-only medicine in the UK is not permitted. Wegovy is a POM, you receive each dose as part of an ongoing, clinically reviewed prescription. Changing that dose unilaterally, even by a single step, sits outside the terms of that prescription. If you feel your current dose is no longer working, the right route is to contact your prescriber and ask for a formal review. At nume, that review happens with every repeat order, and aftercare support is available seven days a week.
For a fuller breakdown of when a semaglutide dose increase is clinically appropriate, including the signs that suggest you're ready, the guidance consistently points back to the four-week minimum, and a conversation with whoever holds your prescription.
One of the reasons patients want to increase quickly is the assumption that the current dose has stopped working. That feeling is understandable but usually incorrect. Weight loss on semaglutide does not switch off between titration steps, appetite suppression is active at every licensed dose. Progress may feel slower in the first few weeks at a new level simply because the body is adapting, not because the treatment has plateaued.
The trial data also shows that a meaningful share of weight loss occurs across the full duration of treatment, not concentrated at the highest dose. Patients who tolerate a lower maintenance dose without needing to reach 2.4 mg still achieve substantial reductions. There is a detailed look at whether weight loss genuinely increases with higher semaglutide doses if you want the trial numbers by dose level, the relationship is real but not linear, and tolerability at each step matters as much as the dose number itself.
Staying at your prescribed dose, eating enough protein, keeping hydrated and staying as active as you can between injections all contribute more than calendar-hacking the titration schedule. The four-week intervals are not a bureaucratic formality. They are the framework within which the evidence was generated.
Contact your prescriber. That is the only appropriate step. If two weeks in you're experiencing minimal side effects and feel your appetite hasn't shifted, that information is clinically relevant, but the response might be reassurance rather than an increase, because two weeks genuinely is early. Understanding how a semaglutide dose increase actually works in practice means your prescriber will want to know about any side effects you've had, your current weight trend, and how you're finding the injection routine before making any decision.
At nume, every repeat order includes a clinical re-review by a GPhC-registered Independent Prescriber. That is when dose decisions are made, not between orders, and not on a two-week clock. If you have concerns before your next order, our aftercare team is available seven days a week via our contact page. For context on the full dose range available and what each step looks like in practice, the Wegovy doses overview covers the schedule from 0.25 mg through to the 2.4 mg maintenance dose.
If you're not yet on treatment and want to understand your options, speaking to our prescribers is the starting point, a free consultation, reviewed the same day by a clinician, not a questionnaire system.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.